ŽRú±@Šî¶@‹qˆõ‹³Žö

@

ŽRú±@Šî¶@i‚â‚Ü‚³‚«@‚à‚Æ‚¨j

y—ª—ðz

1978”N@“Œ‹žH‹Æ‘åŠw HŠw•”‘²‹Æ
1980
”N “¯CŽm‰Û’öC—¹ “¯”N ‹¦˜a”­yH‹ÆŠ”Ž®‰ïŽÐ“üŽÐi“Œ‹žŒ¤‹†Š‚Ö”z‘®j
1990
”N3ŒŽ`1991”N6ŒŽ ‘—§zŠÂŠí•aƒZƒ“ƒ^[Œ¤‹†Š@(¼”öšæ”VŠ’·)@ŠO—ˆŒ¤‹†ˆõ
1992”N “Œ‹žŒ¤‹†Š@Žå”CŒ¤‹†ˆõ
1999”N HŠw”ŽŽmŽö—^ i“Œ‹ž‘åŠwj
1999”N`2004”N ˆã–òŒ¤‹†ŠJ”­–{•”Œ“–±@(R‘̈ã–ò—Õ°ŠJ”­Œ¤‹†)
2004
”N æ’[ƒoƒCƒIŒ¤‹†Š •›Š’·
2005”N ƒoƒCƒIƒtƒƒ“ƒeƒBƒAŒ¤‹†Š@•›Š’·
2006”N ‘åã‘åŠwE’`”’Ž¿Œ¤‹†Š i‹qˆõj‹³Žö iŒ“–±j

‹¦˜a”­yH‹ÆŠ”Ž®‰ïŽÐ@

@

ŋ߂TƒJ”NŠÔ‚ÌŽå‚ÈŒ¤‹†˜_•¶@u2002-2006v

1.    K. Shibata, K. Maruyama-Takahashi, M. Yamasaki and N. Hirayama: G-CSF receptor-binding peptides designed with artificial amino-acid linkers. Biochem. Biophys. Res. Commun., 341, 483-488 (2006)

2.     T. Shinkawa, K. Nakamura, N. Yamane, E. Shoji-Hosaka, Y. Kanda, M. Sakurada, K. Uchida, H. Anazawa, M. Satoh, M. Yamasaki, N. Hanai, and K. Shitara: The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody dependent Cellular Cytotoxicity. J. Biol. Chem., 278, 3466-3473@(2003)

3.     K. Shibata, T. Suzawa, S. Soga, T. Mizukami, K. Yamada, N. Hanai, and M. Yamasaki:@Improvement of Biological Activity and Proteolytic Stability of Peptides by Coupling with a Cyclic Peptide.@Bioorg. Med. Chem. Lett., 13, 2583-2586@(2003)

4.     M. Abe, N. Oda, K. Shibata, M. Yamasaki and Y. Sato: Augmented Binding and Activation of Latent Transforming Growth Factor-ƒÀ by a Tryptic Fragment of Latency Assosiated Peptide. Endothelium, 9, 25-36 (2002)

5.      T. Suzawa, S. Nagamura, H. Saito, S. Ohta, N. Hanai, and M. Yamasaki: Enhanced tumor cell@selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker. J. Controlled Release, 79, 229-242 (2002)